Psychometric properties and participant characteristics for persons with intellectual disability using the Matson Evaluation of Drug Side-effects (MEDS)

Journal of Developmental and Physical Disabilities

Volumn 20, Issue 3, 2008, Pages 243-255

  Matson, Johnny L ^a   Rivet, Tessa T ^a   Fodstad, Jill C ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Cutoff scores; Intellectual disabilities; MEDS; Psychotropic medications; Side effects

Indexed keywords

EID: 42449139642     PISSN: 1056263X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10882-007-9092-2     Document Type: Article

References (41)

1. Advokat, C. D., Mayville, E. A., & Matson, J. L. (2000). Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with intellectual disability. Research in Developmental Disabilities, 21, 75-84.
2. American Psychological Association (2000). Diagnostic and statistical manual of Mental disorders (4th ed.). Washington, DC: American Psychological Association.
3. Ben-Itzchak, E., & Zachor, D. A. (2007). The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Research in Developmental Disabilities, 28, 287-303.
4. Bramston, P., Bruggerman, K., & Pretly, G. (2002). Community perspectives and subjective quality of life. International Journal of Disability Development and Education, 49, 385-397.
5. Cicchetti, D., Bronen, R., Spencer, S., Haut, S., Berg, A., et al. (2006). Rating scales, scales of measurement, issues of reliability: Resolving some critical issues for clinicians and researchers. Journal of Nervous and Mental Disease, 194, 557-564.
6. Chouinard, G., & Margolese, H. C. (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research, 76, 247-265.
7. Dosen, A., & Day, K. (2001). Treating mental illness and behavior disorders in children and adults with mental retardation (pp. 3-24). Washington: American Psychiatric Press.
8. Duker, P. C., & van den Munckhof, M. (2007). Heart rate and the role of the active receiver during contingent electric shock for severe self-injurious behavior. Research in Developmental Disabilities, 28, 43-49.
9. Fox, R. A., Keller, K. M., Grede, P. L., & Bartosz, A. M. (2007). A mental health clinic for toddlers with developmental delays and behavior problems. Research in Developmental Disabilities, 28, 119-129.
10. Glenn, E., Bihm, E. M., & Lammers, W. J. (2003). Depression, anxiety, and relevant cognition in persons with mental retardation. Journal of Autism and Developmental Disorders, 33, 69-75.
11. Hoch, J., & Symons, F. J. (2007). Matching analysis of socially appropriate and destructive behavior in developmental disabilities. Research in Developmental Disabilities, 28, 238-248.
12. Hove, O. (2007). Survey on dysfunctional eating behavior in adult persons with intellectual disability living in the community. Research in Developmental Disabilities, 28, 1-8.
13. Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychological research. Journal of Consulting and Clinical Psychology, 59, 12-19.
14. Kalachnik, J. E. (1999). Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 348-359.
15. Kampert, A.L. & Goreczny, A.J. (2007). Community involvement and socialization among individuals with mental retardation. Research in Developmental Disabilities
16. Kastner, T., Walsh, K., & Fraser, M. (2001). Undiagnosed medical conditions and medication side effects presenting as behavioral/psychiatric problems in people with mental retardation. Mental Health Aspects of Developmental Disabilities, 4, 101-107.
17. Kaushik, S., Lindenmayer, J. P., & Kahn, A. (2007). Management of antipsychotic side effects. Primary Psychiatry, 14, 77-82.
18. Kaye, S. (1997). The status of people with disabilities in the United States. Disability Watch (pp. 1-37). Volcano, CA: Volcano Press.
19. LaMalfa, G., Lassi, S., Salvini, R., Giganti, C., Bertilli, M., & Albertini, G. (2007). The relationship between autism and psychiatric disorders in intellectually disabled adults. Research in Autism Spectrum Disorders, 1, 218-228.
20. Lancioni, G. E., Singh, N. N., O'Reilly, M. F., Sigatoos, J., Oliva, D., & Baccani, S. (2007). Enabling students with multiple disabilities to request and choose among environmental stimuli through microswitch and computer technology. Research in Developmental Disabilities, 28, 50-58.
21. LeBlanc, L. A., Geiger, K. B., Sautter, R. A., & Sidener, T. M. (2007). Using the Natural Language Paradigm (NLP) to increase vocalizations of older adults with cognitive impairments. Research in Developmental Disabilities, 28, 437-444.
22. Matson, J. L. (1995). The Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Baton Rouge, LA: Disability Consultants, LLC.
23. Matson, J. L., & Baglio, C. S. (1998). Administrator's manual: Matson Evaluation of Drug Side Effects (MEDS). Baton Rouge, LA: Scientific Publishers.
24. Matson, J. L., Fodstad, J. C., & Rivet, T. T. (2007). The convergent and divergent validity of the Matson evaluation of drug side effects and the Dyskinesia Identification System Condensed User Scale. Manuscript Submitted for Publication (copy on file with author).
25. Matson, J. L., Mayville, E. A., Bamburg, J. W., & Eckholdt, C. S. (2001). An analysis of side-effect profiles of anti-seizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS). Journal of Intellectual & Developmental Disability, 26, 283-295.
26. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson Evaluation of Drug Side Effects (MEDS). Research in Developmental Disabilities, 20, 501-506.
27. Matson, J. C., & Minshawi, N. F. (2007). Functional assessment of challenging behavior: Toward a strategy for applied settings. Research in Developmental Disabilities, 28, 353-361.
28. McGillivray, J. A., & McCabe, M. P. (2006). Emerging trends in the use of drugs to manage the challenging behaviour of people with intellectual disability. Journal of Applied Research in Intellectual Disabilities, 19, 163-172.
29. McGillivray, J. A., & McCabe, M. P. (2007). Early detection of depression and associated risk factors in adults with mild/moderate intellectual disability. Research in Developmental Disabilities, 28, 59-70.
30. Miller, C. H., & Fleischhacker, W. W. (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Safety, 22, 73-81.
31. Nottestad, J. A., & Linaker, O. M. (2003). Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research, 47, 464-471.
32. Ono, Y. (1998). Behavior disorders in people with mental retardation receiving antipsychotic drugs. Research in Developmental Disabilities, 19, 123-130.
33. Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention, and management. Drug Safety, 28, 191-208.
34. Roebel, A. M., & MacLean Jr., W. E. (2007). Spontaneous eye-blinking and stereotyped behavior in older persons with mental retardation. Research in Developmental Disabilities, 28, 37-42.
35. Ruedrick, S., Diana, L., Rossvanes, C. F., & Toliver, J. (2005). The abnormal involuntary movement scale (AIMS) and tardive dyskinesia in persons with developmental disability: The benefit of videotaped exams. Mental Health Aspects of Developmental Disabilities, 8, 94-99.
36. Soares-Weiser, K., & Fernandez, H. H. (2007). Tardive dyskinesia. Seminars in Neurology, 27, 159-169.
37. Sparrow, S., Balla, D., & Cicchetti, D. V. (1984). The Vineland Adaptive Behavior Scales (Survey Form). Circle Pines, MN: American Guidance Service.
38. Sprague, R. L., & Kalachnik, J. E. (1991). Reliability, validity, and a total score cutoff for the Dyskinesia Identification System: Condensed user scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin, 27, 51-58.
39. Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., & Fleischhacker, W. (2007). Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 61, 1356-1370.
40. Tueth, M. J. (1994). Emergencies caused by side effects of psychiatric medications. American Journal of Emergency Medicine, 12, 212-216.
41. Valdovinos, M. G., Caruso, M., Roberts, C., Kim, G., & Kennedy, C. H. (2005). Medical and behavioral symptoms as potential medication side effects in adults with developmental disabilities. American Journal on Mental Retardation, 110, 164-170.